All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
#EHA2024: Treatments for relapsed or refractory ALL
By Louise Niven
Bookmark this article
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to the treatment of relapsed or refractory ALL, here.
CONGRESS | POSTER | #EHA2024 | Hai Yi explored a shortened period of f blinatumomab treatment and sequential allo-HSCT in R/R B-cell AL. CR rate was 86.1% (56/65) with 52 patients (60%) achieving MRD negative status. Grade 1 CRS detected in 52.3% (34/65) patients, but grade 2 or… pic.twitter.com/yNSjtSrqkB
— ALL Hub (@ALL_Hub_) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Lihong An reports the long-term efficacy of combination treatment with CD19 and CD22 CAR T-cells in patients with relapsed B-ALL after allo-HCT. In 24 patients who completed therapy, 3- and 5-year OS and EFS were 79% and 54% and 75% and 50%,… pic.twitter.com/KMYAMPnTlK
— ALL Hub (@ALL_Hub_) June 17, 2024
CONGRESS #EHA2024 | Ibrahim Aldoss @cityofhope presents findings of the phase II portion of a phase I/II trial (NCT04984356) evaluating safety and efficacy of WU-CART-007 in pts with R/R T-ALL/LBL (N=13). Treatment-related AEs of Grade ≥3 occurred in 61.5% of pts, and CRS was… pic.twitter.com/V6SBHlClq4
— ALL Hub (@ALL_Hub_) June 14, 2024
CONGRESS #EHA2024 | Claire Roddie @drclaireroddie @ucl presents findings of the phase Ib/II FELIX study (NCT04404660) of Obecabtagene autoleucel in adult patients with R/R B-ALL. 12-month EFS was 49.5% with censoring for allo-SCT, while 12-month OS was 61.1% without censoring for… pic.twitter.com/ig9pAis5Za
— ALL Hub (@ALL_Hub_) June 14, 2024
CONGRESS | POSTER | #EHA2024 | Gaétan Basile @CHUBordeaux presents the efficacy and tolerance data for modified HCVAD-blinatumomab-TKI combination for relapsed/refractory ph+ b-cell #ALL. A high-rate of CR with MRD negativity was observed, however cardiovascular events and… pic.twitter.com/4QUOtJoSHE
— ALL Hub (@ALL_Hub_) June 14, 2024
CONGRESS | POSTER | #EHA2024 | @thomas_cluzeau @CHUdeNice reports results from the ATHENA study describing real-world utilization of blinatumomab in adult and pediatric patients with ALL in France. Four key uses of blinatumomab were identified: HSCT preparation, adults (31.3%),… pic.twitter.com/5gfrefaNJT
— ALL Hub (@ALL_Hub_) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Victor Urbalejo shares findings from a retrospective analysis of blinatumomab in patients with ALL in Latin America (N=138). Blinatumomab elicited significant responses with good tolerability. #allsm #leusm #MedicalCongress pic.twitter.com/dSXhnywevF
— ALL Hub (@ALL_Hub_) June 17, 2024
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox